Valuation: AbbVie Inc.

Market Cap 441B 14,603B 381B 358B 325B 612B 42,153B 622B 4,192B 1,639B 21,109B 1,655B 1,619B 70,147B P/E 2026 *
31.8x
P/E 2027 * 23.6x
Enterprise Value 501B 16,606B 433B 407B 370B 696B 47,937B 707B 4,767B 1,864B 24,005B 1,882B 1,841B 79,773B EV / Sales 2026 *
7.42x
EV / Sales 2027 * 6.7x
Free-Float
95.71%
Yield 2026 *
2.75%
Yield 2027 * 2.89%
1 day-0.61%
Current month-4.65%
3 months+17.99%
1 week 8.05
Extreme 8.05
8.45
1 month 8
Extreme 8
8.9
Current year 6.65
Extreme 6.65
8.9
1 year 6.65
Extreme 6.65
8.9
3 years 6.65
Extreme 6.65
8.9
5 years 6.65
Extreme 6.65
8.9
10 years 6.65
Extreme 6.65
8.9
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%0.00% - - 441B
-2.25%-0.47%+68.30%+116.05% 1,052B
-0.66%+0.43%+47.39%+51.02% 627B
-0.54%+1.39%+20.69%+64.61% 441B
-1.99%-3.32%+38.71%+36.26% 349B
-1.05%-2.81%+23.07%+35.91% 287B
-2.12%-3.67%-1.14%+5.35% 241B
-0.63%+1.04%+40.05%+56.67% 224B
-1.19%-3.41%-9.57%-53.50% 202B
+0.16%+3.87%+16.89%+77.38% 172B
Average -1.09%+0.26%+27.15%+43.31% 399.46B
Weighted average by Cap. -1.28%+0.04%+39.09%+61.76%

Financials

2026 *2027 *
Net sales 67.58B 2,239B 58.37B 54.85B 49.89B 93.79B 6,463B 95.33B 643B 251B 3,236B 254B 248B 10,755B 73.51B 2,435B 63.49B 59.66B 54.26B 102B 7,029B 104B 699B 273B 3,520B 276B 270B 11,698B
Net income 13.86B 459B 11.97B 11.25B 10.23B 19.24B 1,325B 19.55B 132B 51.54B 664B 52.04B 50.91B 2,206B 18.9B 626B 16.32B 15.34B 13.95B 26.22B 1,807B 26.66B 180B 70.26B 905B 70.95B 69.41B 3,007B
Net Debt 60.49B 2,004B 52.25B 49.09B 44.65B 83.94B 5,784B 85.33B 575B 225B 2,897B 227B 222B 9,626B 51.66B 1,711B 44.62B 41.93B 38.13B 71.69B 4,940B 72.87B 491B 192B 2,474B 194B 190B 8,221B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-08-14 THB 8.200 -0.61% 158,906
26-08-13 THB 8.250 +1.23% 18,369
26-08-11 THB 8.150 0.00% 40,487
26-08-10 THB 8.150 -0.61% 41,716
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
249.46USD
Average target price
276.24USD
Spread / Average Target
+10.74%

Quarterly revenue - Rate of surprise